AMENDMENT TO AMENDED AND RESTATED MANUFACTURING AND
SUPPLY AGREEMENT

This Amendment to the Amended and Restated Manufacturing and Supply Agreement (the “Amendment”) is entered into as of the 2^nd day of February, 2012 and is deemed to have come into effect on 1 January 2012 (the “Effective Date”), by and among Novartis Vaccines and Diagnostics, Inc., with its principal place of business located at 350 Massachusetts Avenue, Cambridge, MA 02139 USA (hereinafter “Novartis”), and BioMimetic Therapeutics, Inc a Delaware corporation, with its principal place of business located at 389 Nichol Mill Lane, Franklin, Tennessee 37067 (hereinafter “BMTI”).

BACKGROUND

WHEREAS, BMTI and Chiron Corporation (“Chiron”) previously entered into an exclusive Manufacturing and Supply Agreement effective July 28, 2004 (“Original Agreement”)

WHEREAS, on 20 April 2006 Novartis acquired Chiron and thereby assumed Chiron's rights and responsibilities under the Original Agreement. Under the Original Agreement Novartis had manufactured and supplied BMTI with Product consisting of purified bulk recombinant human platelet growth factor as described in Novartis' FDA — approved Biological License Application therefor, for use in the Exclusive Fields (as defined in the Agreement).

WHEREAS, the parties amended and restated the Original Agreement and entered into the Amended and Restated Manufacturing and Supply Agreement effective December 1, 2009 to better define the parties' rights and obligations regarding the Product, (the “Agreement”);

WHEREAS, the parties have agreed that Novartis will transfer the manufacturing and testing activities for Products currently performed at Bayer's facility in Emeryville, California (a subcontractor of Novartis) to the Facility (as defined in the Agreement) (the “Drug Substance Transfer”).

WHEREAS, subject to the terms and conditions set forth herein, the parties hereto mutually desire to amend, modify and restate certain terms and conditions of the Agreement, as provided below.

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

Unless otherwise defined herein, capitalized terms used in this Amendment shall have the meanings set forth in the Agreement.

The Parties agree that, as of the Effective Date, the Agreement is amended as set forth in this Section 2.

“Each party shall bear its own costs associated with qualifying and licensing the Drug Substance Transfer changes covered by Novartis Change Control Numbers 25413, 32986, 306321, 312336, and 287336 for use in the Exclusive Field.”

“3.2 Minimum Shelf Life. Subject to the specific exceptions at paragraph 1 of Annex 2, at the time of delivery to BMTI’s designated carrier, the Product shall have a remaining shelf life of not less than ** months.”

“For the purposes of calculating Novartis’ minimum supply obligations pursuant to Section 11.2(a) of this Agreement, BMTI shall be deemed to have purchased ** grams of the Product on 31 December 2011.”

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized representatives, as of the date first written above.

SCHEDULE 1
ANNEX 2
COMPENSATION

These prices shall be adjusted annually in accordance with paragraph 8 below.

Notwithstanding Section 3.2 of the Agreement, BMTI agrees to accept delivery of Product with a remaining shelf life of less than ** months, as follows:

For the avoidance of doubt, the supply of Products with a remaining shelf life of less than ** months shall count towards BMTI's Minimum Purchase Requirements set out at paragraph 3 of this Annex 2.

If BMTI's dosage for Product in all of its commercial product package configurations is less than or equal to ** mg/package, the sales price will be $** /gram.

(Any analytical tests requested by BMTI and performed by Novartis, other than Novartis' standard COA release testing shall be charged at the Additional Services Rate.)

BMTI shall pay Novartis for third-party royalties in accordance with its License Agreements, as provided in Section 5.3 of the Agreement, including the following:

BMTI shall pay Novartis for any travel authorized by BMTI, at cost plus 15%.

Subject to paragraph 8 below, BMTI shall pay Novartis for any additional services approved in writing by BMTI at the rate of $**/person-hour, for services performed by Novartis, and at cost plus **%, for services performed by independent contractors (jointly, the “Additional Services Rate”).

Payments shall be due within ** days of BMTI's receipt of the applicable invoice.

If BMTI terminates the Agreement pursuant to Section 10/2/3(a) thereof, BMTI shall pay Novartis a non-refundable, non-creditable termination fee equal to **, within ** days of such termination.

Novartis may revise the prices of the Products and the Additional Services Rate annually by any amount of increase in the United States Producer Price Index 2834 (Pharmaceutical Preparations) during the preceding year.